• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

国际透析预后和实践模式研究中矿物质与骨代谢紊乱标志物组合及死亡和住院风险

Combinations of mineral and bone disorder markers and risk of death and hospitalizations in the international Dialysis Outcomes and Practice Patterns Study.

作者信息

Fuller Douglas S, Dluzniewski Paul J, Cooper Kerry, Bradbury Brian D, Robinson Bruce M, Tentori Francesca

机构信息

Arbor Research Collaborative for Health, Ann Arbor, MI, USA.

Center for Observational Research, Amgen, Thousand Oaks, CA, USA.

出版信息

Clin Kidney J. 2019 Nov 8;13(6):1056-1062. doi: 10.1093/ckj/sfz112. eCollection 2020 Dec.

DOI:10.1093/ckj/sfz112
PMID:33391749
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7769536/
Abstract

BACKGROUND

Prior studies have developed a chronic kidney disease-mineral and bone disorder (CKD-MBD) composite score based on combinations of calcium (Ca), phosphorus (P) and parathyroid hormone (PTH) that have been shown to be associated with an increased risk of clinical outcomes in the USA. We examined this association in a contemporary, international cohort of hemodialysis patients.

METHODS

We studied 19 313 patients surviving ≥12 months in the Dialysis Outcomes and Practice Patterns Study Phases 3-5 (2005-15) from Europe, Canada and the USA. The CKD-MBD composite score was defined as the number of markers above target levels (P, 3.5-5.5 mg/dL; Ca, 8.4-10.2 mg/dL; PTH, 150-600 pg/mL). Using Cox models, we estimated hazard ratios (HRs) for death and a composite event (death or hospitalization), contrasting MBD 2/3 (2-3 parameters above target) with MBD 0 (all in target), adjusted for a disease risk score (DRS).

RESULTS

MBD 2/3 above target was observed in 10-14% of patients across regions and was associated with greater DRS-adjusted mortality {HR 1.41 [95% confidence interval (CI) 1.10-1.82]} and composite events [HR 1.23 (95% CI 1.10-1.38)] in the USA compared with MBD 0; the mortality association was stronger for patients ≥ 65 years of age [HR 1.82 (95% CI 1.28-2.58)] compared with patients <65 years of age [HR 1.11 (95% CI 0.80-1.55)]. HRs observed in Canada and Europe were generally consistent but weaker. Estimates for MBD 2/3 outside target (above or below) were slightly lower in all regions.

CONCLUSIONS

Simultaneous consideration of Ca, P and PTH may help in identifying patients on dialysis with a higher risk of major clinical outcomes related to CKD-MBD.

摘要

背景

先前的研究基于钙(Ca)、磷(P)和甲状旁腺激素(PTH)的组合制定了慢性肾脏病-矿物质和骨异常(CKD-MBD)综合评分,在美国,这些组合已被证明与临床结局风险增加相关。我们在一个当代国际血液透析患者队列中研究了这种关联。

方法

我们研究了来自欧洲、加拿大和美国的透析预后与实践模式研究第3-5阶段(2005-2015年)中存活≥12个月的19313例患者。CKD-MBD综合评分定义为高于目标水平的标志物数量(P,3.5-5.5mg/dL;Ca,8.4-10.2mg/dL;PTH,150-600pg/mL)。使用Cox模型,我们估计了死亡和复合事件(死亡或住院)的风险比(HR),将MBD 2/3(2-3个参数高于目标)与MBD 0(所有参数均在目标范围内)进行对比,并根据疾病风险评分(DRS)进行调整。

结果

各地区10%-14%的患者出现高于目标的MBD 2/3,与MBD 0相比,在美国,MBD 2/3与更高的经DRS调整的死亡率{HR 1.41[95%置信区间(CI)1.10-1.82]}和复合事件[HR 1.23(95%CI 1.10-1.38)]相关;与年龄<65岁的患者[HR 1.11(95%CI 0.80-1.55)]相比,65岁及以上患者的死亡率关联更强[HR 1.82(95%CI 1.28-2.58)]。在加拿大和欧洲观察到的HR总体一致,但较弱。所有地区高于或低于目标的MBD 2/3的估计值略低。

结论

同时考虑Ca、P和PTH可能有助于识别血液透析患者中与CKD-MBD相关的主要临床结局风险较高的患者。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7618/7769536/41079a24a268/sfz112f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7618/7769536/1cbaebc5379b/sfz112f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7618/7769536/41079a24a268/sfz112f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7618/7769536/1cbaebc5379b/sfz112f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7618/7769536/41079a24a268/sfz112f2.jpg

相似文献

1
Combinations of mineral and bone disorder markers and risk of death and hospitalizations in the international Dialysis Outcomes and Practice Patterns Study.国际透析预后和实践模式研究中矿物质与骨代谢紊乱标志物组合及死亡和住院风险
Clin Kidney J. 2019 Nov 8;13(6):1056-1062. doi: 10.1093/ckj/sfz112. eCollection 2020 Dec.
2
Detecting high-risk chronic kidney disease-mineral bone disorder phenotypes among patients on dialysis: a historical cohort study.检测透析患者中的高风险慢性肾脏病-矿物质和骨异常表型:一项历史队列研究。
Nephrol Dial Transplant. 2019 Apr 1;34(4):682-691. doi: 10.1093/ndt/gfy273.
3
Mineral bone disorder and its management among hemodialysis patients in the Gulf Cooperation Council: Initial findings from the dialysis outcomes and practice patterns study (2012-2015).海湾合作委员会地区血液透析患者的矿物质骨代谢紊乱及其管理:透析结局与实践模式研究(2012 - 2015年)的初步结果
Saudi J Kidney Dis Transpl. 2016 Nov;27(6 Suppl 1):62-80. doi: 10.4103/1319-2442.194902.
4
Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS).不同血清钙、磷和甲状旁腺激素水平的透析患者的死亡风险:透析结局和实践模式研究(DOPPS)
Am J Kidney Dis. 2008 Sep;52(3):519-30. doi: 10.1053/j.ajkd.2008.03.020. Epub 2008 Jun 2.
5
Etelcalcetide Utilization, Dosing Titration, and Chronic Kidney Disease-Mineral and Bone Disease (CKD-MBD) Marker Responses in US Hemodialysis Patients.依特卡塞特在美接受血液透析患者中的应用、剂量滴定和慢性肾脏病-矿物质和骨异常(CKD-MBD)标志物反应。
Am J Kidney Dis. 2022 Mar;79(3):362-373. doi: 10.1053/j.ajkd.2021.05.020. Epub 2021 Jul 15.
6
Optimal targets of chronic kidney disease-mineral and bone disorder markers for Chinese patients with maintenance peritoneal dialysis: a single-center retrospective cohort study.中国维持性腹膜透析患者慢性肾脏病-矿物质和骨异常标志物的最佳目标:一项单中心回顾性队列研究。
Ren Fail. 2022 Dec;44(1):336-345. doi: 10.1080/0886022X.2022.2041438.
7
Survey of attitudes of physicians toward the current evaluation and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD).医生对慢性肾脏病-矿物质和骨异常(CKD-MBD)当前评估与治疗的态度调查
Saudi J Kidney Dis Transpl. 2010 Jan;21(1):93-101.
8
Facility-level CKD-MBD composite score and risk of adverse clinical outcomes among patients on hemodialysis.血液透析患者的机构层面慢性肾脏病-矿物质和骨异常综合评分与不良临床结局风险
BMC Nephrol. 2016 Nov 4;17(1):166. doi: 10.1186/s12882-016-0382-8.
9
International variation in the management of mineral bone disorder in patients with chronic kidney disease: Results from CKDopps.慢性肾脏病患者矿物质和骨异常管理的国际差异:来自 CKDopps 的结果。
Bone. 2019 Dec;129:115058. doi: 10.1016/j.bone.2019.115058. Epub 2019 Sep 4.
10
[Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].3、4、5期慢性肾脏病(未透析)患者矿物质代谢的变化
Nefrologia. 2008;28 Suppl 3:67-78.

引用本文的文献

1
Is thymectomy necessary during parathyroidectomy for secondary hyperparathyroidism in patients with end-stage kidney disease?对于终末期肾病患者的继发性甲状旁腺功能亢进,在甲状旁腺切除术中是否有必要进行胸腺切除术?
Surgery. 2025 Jan;177:108839. doi: 10.1016/j.surg.2024.06.067. Epub 2024 Oct 10.
2
Secondary Hyperparathyroidism and Cognitive Decline.继发性甲状旁腺功能亢进与认知功能衰退
Curr Transplant Rep. 2023 Jun;10(2):60-68. doi: 10.1007/s40472-023-00394-5. Epub 2023 Mar 15.
3
Real-world usage of Chronic Kidney Disease - Mineral Bone Disorder (CKD-MBD) biomarkers in nephrology practices.

本文引用的文献

1
Race, Mineral Homeostasis and Mortality in Patients with End-Stage Renal Disease on Dialysis.透析治疗的终末期肾病患者的种族、矿物质稳态与死亡率
Am J Nephrol. 2015;42(1):25-34. doi: 10.1159/000438999. Epub 2015 Aug 20.
2
Refining the definition of clinically important mineral and bone disorder in hemodialysis patients.细化血液透析患者临床重要矿物质和骨代谢紊乱的定义。
Nephrol Dial Transplant. 2015 Aug;30(8):1336-44. doi: 10.1093/ndt/gfv034. Epub 2015 Mar 27.
3
The Effects of Cinacalcet in Older and Younger Patients on Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial.
慢性肾脏病 - 矿物质和骨异常(CKD-MBD)生物标志物在肾脏病诊疗实践中的实际应用。
Clin Kidney J. 2023 Nov 29;17(1):sfad290. doi: 10.1093/ckj/sfad290. eCollection 2024 Jan.
4
Neck Reoperation for Recurrent or Persistent Renal Hyperparathyroidism.复发性或持续性肾性甲状旁腺功能亢进的颈部再次手术
World J Surg. 2023 Nov;47(11):2784-2791. doi: 10.1007/s00268-023-07172-5. Epub 2023 Sep 15.
5
Serum Phosphorus and Albumin in Patients Undergoing Peritoneal Dialysis: Interaction and Association With Mortality.接受腹膜透析患者的血清磷和白蛋白:相互作用及与死亡率的关联
Front Med (Lausanne). 2021 Dec 1;8:760394. doi: 10.3389/fmed.2021.760394. eCollection 2021.
6
Association between the risk of death and serum calcium, phosphate, and intact parathyroid hormone levels in older patients undergoing maintenance hemodialysis: a cohort study in Beijing.维持性血液透析老年患者死亡风险与血清钙、磷及甲状旁腺激素水平的关联:一项在北京开展的队列研究
Ther Adv Endocrinol Metab. 2021 Jun 25;12:20420188211025161. doi: 10.1177/20420188211025161. eCollection 2021.
7
Phosphate, Microbiota and CKD.磷酸盐、微生物群与慢性肾脏病。
Nutrients. 2021 Apr 13;13(4):1273. doi: 10.3390/nu13041273.
8
Study design and baseline characteristics of patients on dialysis in the ASCEND-D trial.ASCEND-D 试验中透析患者的研究设计和基线特征。
Nephrol Dial Transplant. 2022 Apr 25;37(5):960-972. doi: 10.1093/ndt/gfab065.
9
The unaccomplished mission of reducing mortality in patients on kidney replacement therapy.在接受肾脏替代治疗的患者中降低死亡率这一未完成的使命。
Clin Kidney J. 2020 Nov 30;13(6):948-951. doi: 10.1093/ckj/sfaa235. eCollection 2020 Dec.
西那卡塞在老年和年轻血液透析患者中的作用:盐酸西那卡塞治疗降低心血管事件的评估(EVOLVE)试验
Clin J Am Soc Nephrol. 2015 May 7;10(5):791-9. doi: 10.2215/CJN.07730814. Epub 2015 Feb 20.
4
Recent changes in therapeutic approaches and association with outcomes among patients with secondary hyperparathyroidism on chronic hemodialysis: the DOPPS study.慢性血液透析患者继发性甲状旁腺功能亢进治疗方法的近期变化及其与预后的关系:透析预后与实践模式研究(DOPPS)
Clin J Am Soc Nephrol. 2015 Jan 7;10(1):98-109. doi: 10.2215/CJN.12941213. Epub 2014 Dec 16.
5
Increased bone fractures among elderly United States hemodialysis patients.美国老年血液透析患者骨折发生率增加。
Nephrol Dial Transplant. 2014 Jan;29(1):146-51. doi: 10.1093/ndt/gft352. Epub 2013 Sep 26.
6
CKD-mineral and bone disorder and risk of death and cardiovascular hospitalization in patients on hemodialysis.血液透析患者的慢性肾脏病-矿物质和骨异常与死亡和心血管住院风险。
Clin J Am Soc Nephrol. 2013 Dec;8(12):2132-40. doi: 10.2215/CJN.04260413. Epub 2013 Sep 19.
7
Role of disease risk scores in comparative effectiveness research with emerging therapies.疾病风险评分在新兴疗法的比较有效性研究中的作用。
Pharmacoepidemiol Drug Saf. 2012 May;21 Suppl 2(Suppl 2):138-47. doi: 10.1002/pds.3231.
8
The Dialysis Outcomes and Practice Patterns Study (DOPPS) Practice Monitor: rationale and methods for an initiative to monitor the new US bundled dialysis payment system.《透析结局和实践模式研究(DOPPS)实践监测》:一项监测美国新捆绑式透析支付系统的倡议的基本原理和方法。
Am J Kidney Dis. 2011 Jun;57(6):822-31. doi: 10.1053/j.ajkd.2011.03.001. Epub 2011 May 6.
9
Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population.血清 iPTH、钙和磷与欧洲血液透析人群的死亡率风险。
Nephrol Dial Transplant. 2011 Jun;26(6):1948-55. doi: 10.1093/ndt/gfq219. Epub 2010 Apr 25.
10
An improved comorbidity index for outcome analyses among dialysis patients.一种改进的透析患者预后分析合并症指数。
Kidney Int. 2010 Jan;77(2):141-51. doi: 10.1038/ki.2009.413. Epub 2009 Nov 11.